Moneycontrol
Nov 30, 2016 04:27 PM IST | Source: Moneycontrol.com

Buy, sell, hold: 9 stocks you can watch out today

Morgan Stanley has overweight rating on Bharat Financial with target at Rs 1125 per share. It says share price will rise relative to the industry over the next 30 days. Collection efficiency has been progressively improving.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Moneycontrol Bureau

Here are brokerage views on 9 stocks for your portfolio

United Spirits

Morgan Stanley says improved capital efficiencies and debt reduction drives overweight rating. It says there are  initial signs of an improving industry construct with price hikes and  policy changes.


LIC Housing

Morgan Stanley stays overweight with valuation of 2.2x FY18 BV attractive as return ratios resilient even on stressed earnings.


Tech Mahindra

Morgan Stanley is overweight with target at Rs 545 per share.


Bharat Financial

Morgan Stanley has overweight rating with target at Rs 1125 per share. It says share price will rise relative to the industry over the next 30 days. Collection efficiency has been progressively improving.

Power Grid

Credit Suisse maintains outperform with target unchanged at Rs 225 per share as ordering in FY17-YTD has been strong at Rs 19000 crore. It estimates 14.5 percent CAGR growth over FY17-20.


Arvind

Credit Suisse maintains outperform with target increased to Rs 430 from Rs 380 per share.  It has cut growth and  margin estimates for second half  of FY17 and FY18. It says high brand growth, improving financials make its  positive.


Bharat Financial

Credit Suisse has upgraded stock to neutral from underweight but cuts target Rs 700 from Rs 710 per share. It has cut EPS estimates by 17 percent for FY17 and 10-11 percent for FY18/FY19. It says  recent correction now implies limited downside.


Idea

CLSA retains sell call on the stock with target price at Rs 68 per share if it sells its tower biz, it could  reduce debt by 15 percent  to over 3times EBITDA. It says net interest savings due to tower business sale would boost profit by over 4-10 percent.

Torrent Pharma

CLSA upgrade it to buy from outperform with target price unchanged at Rs 1730 per share as India formulations sales continue to gain momentum with 21 percent CAGR from FY13-16.

Sections
Follow us on
Available On